News Releases and More Information:
- James Thomson: Opening access to the cellular building blocks of life; 29 June 2014
- UW stem cell pioneer Thomson earns innovation award; 4 April 2013
- McEwen Award for Innovation; June 2013
- Thomson lab lands $2.2 million NIH grant; 24 July 2012
- Study shows patient’s own cells may hold therapeutic promise after reprogramming, gene correction; 4 April 2011
- UW-Madison researcher Thomson wins prestigious Albany Prize; 16 March 2011
- Wisconsin stem cell pioneer wins Faisal International Prize; 21 January 2011
- UW-Madison Heart Stem Cell Study Among Top Research Advances; 22 January 2010
In the early 1990s, my lab derived ES cells from an Old World monkey (the rhesus macaque) and a New World monkey (the common marmoset), work that led to derivation of human ES cells in 1998. Much of my lab’s research after that derivation was dedicated to establishing human ES cells as an accepted, practical model system. To that end, we developed defined culture conditions, methods for genetic manipulation, and approaches for the in vitro differentiation of human ES cells to key lineages of clinical importance including hematopoietic, neural, cardiac, and placental tissues. More recently, in 2007, my laboratory described the isolation of human induced pluripotent (iPS cells) cells with the basic properties of human ES cells but derived from somatic cells.
My research now focuses on understanding how a cell can maintain or change identity, how a cell chooses between self-renewal and the initial decision to differentiate, and how a differentiated cell with limited developmental potential can be reprogrammed to a pluripotent cell.
My current research interests include:
- Examining the transcriptional networks in ES cells that mediate self-renewal and commitment to each of the basic lineages of the early embryo.
- Mapping the epigenome of ES cells and their early-differentiated derivatives as a participant in the San Diego Epigenome Center.
- Improving methods for generating human iPS cells, and correcting genetic defects in iPS cells generated from patients with degenerative retinal disease.
- Developing new strategies to convert human pluripotent stem and somatic cells into hematopoietic, vascular, and cardiac progenitor cells.
- Understanding clocking mechanisms that control developmental rates.
- Hou Z, Zhang Y, Propson NE, Howden SE, Chu L, Sontheimer EJ, Thomson, JA. “Efficient Genome Engineering in Human Pluripotent Stem Cells Using Cas9 from Neisseria meningitides.” Proc Natl Acad Sci, USA, 110 (39): 15644-9 (2013). PMCID: PMC3785731.
- Cho M, Oh SS, Nie J, Stewart R, Eisenstein MS, Chambers J, Marth J, Walker F, Thomson, JA., Soh H. “Quantitative Selection and Parallel Characterization of Aptamers.” Proc Natl Acad Sci, USA, 110 (46): 18460-5 (2013). PMCID: PMC3831996.
- Phillips MJ, Perez ET, Martin JM, Reshel ST, Wallace KA, Capowski EE, Singh R, Wright LS, Clark EM, Barney PM, Stewart R, Dickerson SJ, Miller MJ, Percin EF, Thomson, JA., Gamm DM. “Modeling human retinal development with patient-specific iPS cells reveals multiple roles for VSX2.” Stem Cells. 2014 Feb 15. PMID: 24532057.
- Magli A, Schnettler E, Swanson SA, Borges L, Hoffman K, Stewart R, Thomson, JA., Keirstead SA, Perlingeiro RC. “Pax3 and Tbx5 specify whether PDGFRα+ cells assume skeletal or cardiac muscle fate in differentiating ES cells.” Stem Cells, 2014 Mar 26. PMID: 24677751.
- Elcheva I, Brok-Volchanskaya V, Kumar A, Liu P, Lee J, Tong D, Vodyanik M, Swanson S, Stewart R, Kyba M, Yakubov E, Cooke JP, Thomson, JA., Slukvin I. “Direct Induction of Hematoendothelial Programs in Human Pluripotent Stem Cells by Transcriptional Regulators.” Nature Communications, 2014 Jul 14; 5:4372. PMID: 25019369.